TEM logo

Tempus AI Inc. (TEM)

$64.76

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TEM

Market cap

$11.81B

EPS

-1.06

P/E ratio

--

Price to sales

8.99

Dividend yield

--

Beta

3.610996

Price on TEM

Previous close

$71.60

Today's open

$69.05

Day's range

$64.55 - $69.22

52 week range

$40.77 - $89.09

Profile about TEM

CEO

Eric Lefkofsky

Employees

3800

Headquarters

Chicago, IL

Exchange

Nasdaq Global Select

Shares outstanding

182401637

Issue type

Common Stock

TEM industries and sectors

Healthcare

Healthcare Providers & Services

News on TEM

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Personalis, Inc. (NasdaqGM: PSNL) to Tempus AI, Inc. (NasdaqGS: TEM). Under the terms of the proposed transaction, shareholders of Personalis will receive $16.25 per common share. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect p.

news source

Business Wire • 6 hours ago

news preview

Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year's meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options. This research leverages Tempus' expansive, de-ident.

news source

Business Wire • Nov 11, 2026

news preview

Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer

Dare to Dream Project will build a real-world data set that can inform pediatric AML research and future clinical trials while helping families better understand their health information WASHINGTON, Nov. 10, 2026 /PRNewswire/ -- Blood Cancer United® today announced the launch of Dare to Dream REALworld: AML, a patient-centered initiative co-founded with Rally Foundation for Childhood Cancer Research. The initiative will engage current and former pediatric acute myeloid leukemia (AML) patients and their families to build real-world evidence that can inform research and future clinical trials, helping accelerate the development of new treatments.

news source

PRNewsWire • Nov 10, 2026

news preview

SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation , a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans.

news source

PRNewsWire • Nov 9, 2026

news preview

Tempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up

Tempus is rated 'hold' as current valuation already prices in considerable future success. The platform's core strength lies in connecting diagnostic data with clinical outcomes, enhancing research value and recurring revenue potential. Q3 2026 showed strong revenue growth in both Diagnostics (+20%) and Data & Applications (+33%), with improving adjusted EBITDA but persistent GAAP losses.

news source

Seeking Alpha • Nov 8, 2026

news preview

Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)

Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data & Applications revenue accelerated to 33% growth. Major partnerships with Bristol Myers Squibb, Moderna, and Merck validate TEM's strategic positioning in AI-driven medicine.

news source

Seeking Alpha • Nov 4, 2026

news preview

Tempus AI Analysts Boost Their Forecasts Following Strong Q3 Results

Tempus AI Inc. (NASDAQ:TEM) on Monday posted upbeat results for the third quarter.

news source

Benzinga • Nov 3, 2026

news preview

Tempus AI Surges on Earnings Beat, But Can the Rally Last?

Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the path to profitability, cash burn, and immense opportunity.

news source

MarketBeat • Nov 3, 2026

news preview

TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside

Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Baron SMID Cap ETF Q3 2026 Contributors And Detractors

Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc., and Netskope, Inc. Top detractors were Axon Enterprise, Inc., Forgent Power Solutions, Inc., and Mercury Systems, Inc.

news source

Seeking Alpha • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Tempus AI Inc.

Open an M1 investment account to buy and sell Tempus AI Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TEM on M1